Completed PHASE3 INTERVENTIONAL 2-arm NCT02671383

Evaluation of Low-dose Darunavir in a Switch Study (DRV)

A Randomised, Open Label Switch Study Comparing Darunavir/Ritonavir 400mg/100mg Daily With Lopinavir/Ritonavir 800mg/200mg Daily, in HIV-positive Participants

Sponsor: Medical Research Council, South Africa

Conditions HIV Infections

Interventions Darunavir Lopinavir

Updated 6 times since 2017 Last updated: Jun 21, 2018 Started: Jun 30, 2016 Primary completion: May 16, 2018 Completion: May 16, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV Infections and is currently completed. Medical Research Council, South Africa leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical Research Council, South Africa
Willem Daniel Francois Venter

Data source: University of Witwatersrand, South Africa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Johannesburg, South Africa